Climb Bio, Inc. (NASDAQ:CLYM – Free Report) – Investment analysts at Leerink Partnrs issued their FY2029 earnings estimates for Climb Bio in a research report issued to clients and investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith expects that the company will post earnings per share of ($2.73) for the year. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Climb Bio’s current full-year earnings is ($1.57) per share.
Separately, Leerink Partners started coverage on Climb Bio in a research note on Monday, December 2nd. They set an “outperform” rating and a $10.00 price objective for the company.
Climb Bio Price Performance
NASDAQ:CLYM opened at $1.75 on Friday. The firm’s 50-day moving average is $2.21. Climb Bio has a 52-week low of $1.73 and a 52-week high of $11.55.
Climb Bio (NASDAQ:CLYM – Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.13) earnings per share (EPS) for the quarter.
Climb Bio Company Profile
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.
See Also
- Five stocks we like better than Climb Bio
- What is diluted earnings per share (Diluted EPS)?
- Uber’s Business, Cash Flow, and AI are Why it Will Set a New High
- The Risks of Owning Bonds
- Weak Guidance from Bristol-Myers Could Be Creating an Opportunity
- What Are the U.K. Market Holidays? How to Invest and Trade
- These are the 3 Stocks Most Likely to Split in 2025
Receive News & Ratings for Climb Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Climb Bio and related companies with MarketBeat.com's FREE daily email newsletter.
